These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30116027)

  • 1. Activation of the mGlu
    Yohn SE; Foster DJ; Covey DP; Moehle MS; Galbraith J; Garcia-Barrantes PM; Cho HP; Bubser M; Blobaum AL; Joffe ME; Cheer JF; Jones CK; Lindsley CW; Conn PJ
    Mol Psychiatry; 2020 Nov; 25(11):2786-2799. PubMed ID: 30116027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M
    Gould RW; Grannan MD; Gunter BW; Ball J; Bubser M; Bridges TM; Wess J; Wood MW; Brandon NJ; Duggan ME; Niswender CM; Lindsley CW; Conn PJ; Jones CK
    Neuropharmacology; 2018 Jan; 128():492-502. PubMed ID: 28729220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics.
    Cho HP; Garcia-Barrantes PM; Brogan JT; Hopkins CR; Niswender CM; Rodriguez AL; Venable DF; Morrison RD; Bubser M; Daniels JS; Jones CK; Conn PJ; Lindsley CW
    ACS Chem Biol; 2014 Oct; 9(10):2334-46. PubMed ID: 25137254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release.
    Foster DJ; Wilson JM; Remke DH; Mahmood MS; Uddin MJ; Wess J; Patel S; Marnett LJ; Niswender CM; Jones CK; Xiang Z; Lindsley CW; Rook JM; Conn PJ
    Neuron; 2016 Sep; 91(6):1244-1252. PubMed ID: 27618677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutual activation of glutamatergic mGlu
    Cieślik P; Woźniak M; Rook JM; Tantawy MN; Conn PJ; Acher F; Tokarski K; Kusek M; Pilc A; Wierońska JM
    Psychopharmacology (Berl); 2018 Oct; 235(10):2897-2913. PubMed ID: 30054675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
    Dogra S; Conn PJ
    Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.
    Byun NE; Grannan M; Bubser M; Barry RL; Thompson A; Rosanelli J; Gowrishankar R; Kelm ND; Damon S; Bridges TM; Melancon BJ; Tarr JC; Brogan JT; Avison MJ; Deutch AY; Wess J; Wood MR; Lindsley CW; Gore JC; Conn PJ; Jones CK
    Neuropsychopharmacology; 2014 Jun; 39(7):1578-93. PubMed ID: 24442096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.
    Bubser M; Bridges TM; Dencker D; Gould RW; Grannan M; Noetzel MJ; Lamsal A; Niswender CM; Daniels JS; Poslusney MS; Melancon BJ; Tarr JC; Byers FW; Wess J; Duggan ME; Dunlop J; Wood MW; Brandon NJ; Wood MR; Lindsley CW; Conn PJ; Jones CK
    ACS Chem Neurosci; 2014 Oct; 5(10):920-42. PubMed ID: 25137629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
    Maksymetz J; Moran SP; Conn PJ
    Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.
    Foster DJ; Conn PJ
    Neuron; 2017 May; 94(3):431-446. PubMed ID: 28472649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mGlu
    Maksymetz J; Byun NE; Luessen DJ; Li B; Barry RL; Gore JC; Niswender CM; Lindsley CW; Joffe ME; Conn PJ
    Cell Rep; 2021 Nov; 37(5):109950. PubMed ID: 34731619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.
    Walker AG; Conn PJ
    Curr Opin Pharmacol; 2015 Feb; 20():40-5. PubMed ID: 25462291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.
    Watt ML; Rorick-Kehn L; Shaw DB; Knitowski KM; Quets AT; Chesterfield AK; McKinzie DL; Felder CC
    Neuropsychopharmacology; 2013 Dec; 38(13):2717-26. PubMed ID: 23907402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinociceptive effects of potent, selective and brain penetrant muscarinic M
    Grauer SM; Sanoja R; Poulin D; Rashid H; Jochnowitz N; Calhoun M; Zwilling D; Varty GB; Rosahl TW; Meziane H; Mittlelhaeuser C; Mazzola R; Morrow J; Smith SM; Henze D; Marcus J
    Brain Res; 2020 Jun; 1737():146814. PubMed ID: 32234514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia.
    Nicoletti F; Orlando R; Di Menna L; Cannella M; Notartomaso S; Mascio G; Iacovelli L; Matrisciano F; Fazio F; Caraci F; Copani A; Battaglia G; Bruno V
    Front Psychiatry; 2019; 10():49. PubMed ID: 30890967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M
    Butler CR; Popiolek M; McAllister LA; LaChapelle EA; Kramer M; Beck EM; Mente S; Brodney MA; Brown M; Gilbert A; Helal C; Ogilvie K; Starr J; Uccello D; Grimwood S; Edgerton J; Garst-Orozco J; Kozak R; Lotarski S; Rossi A; Smith D; O'Connor R; Lazzaro J; Steppan C; Steyn SJ
    J Med Chem; 2024 Jul; 67(13):10831-10847. PubMed ID: 38888621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
    Lesage A; Steckler T
    Eur J Pharmacol; 2010 Aug; 639(1-3):2-16. PubMed ID: 20371230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
    Kanuma K; Aoki T; Shimazaki Y
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mGlu
    Luessen DJ; Gallinger IM; Ferranti AS; Foster DJ; Melancon BJ; Lindsley CW; Niswender CM; Conn PJ
    Neuropsychopharmacology; 2022 Sep; 47(10):1826-1835. PubMed ID: 35643819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
    Noetzel MJ; Rook JM; Vinson PN; Cho HP; Days E; Zhou Y; Rodriguez AL; Lavreysen H; Stauffer SR; Niswender CM; Xiang Z; Daniels JS; Jones CK; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2012 Feb; 81(2):120-33. PubMed ID: 22021324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.